Overview

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Status:
Completed
Trial end date:
2020-12-18
Target enrollment:
Participant gender:
Summary
This clinical trial will evaluate the efficacy and safety of chiauranib added to chemotherapy in patients with relapsed or refractory ovarian cancer, in the meantime, explore the pharmacokinetics characteristic after the combined treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Chipscreen Biosciences, Ltd.
Treatments:
Albumin-Bound Paclitaxel
Chiauranib
Etoposide
Etoposide phosphate
Paclitaxel